Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA?
Which outsourcing facilities list compounded semaglutide with FDA?
FDA’s compounded drugs NDC file (dated Sep 18, 2026, read Nov 15, 2026) lists 38 compounded semaglutide products from 15 outsourcing facilities: Apollo Care, LLC (6), Tailstorm Health INC (5), BPI Labs LLC (4), ANNOVEX PHARMA, INC. (3), OurPharma LLC (3), PQ Pharmacy LLC (3), Eagle Pharma Outsourcing, LLC (2), Empower Pharma (2), Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories (2), Hybrid Pharma (2), Turbare Manufacturing (2), Delta Pharma INC (1), MedisourceRx (1), Signature Rx (1) and Wells Pharma of Houston (1). It also lists 33 tirzepatide products from 10 facilities and 4 liraglutide products; every one carries FDA’s category “OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)”.
FDA on this file: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” and “The NDC Directory contains compounded drug products reported and the assigned NDC within the last two years.” The reporting periods in the file run from 2024-2 to 2026-1, as FDA writes them. A product listed here was reported by the facility; the file does not say how much it made, who it sold to, or whether it still makes it.
FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):
Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.
Outsourcing facilities listing compounded GLP-1 products
Each name links to the facility’s page here (matched by exact name) where one exists.
| BPI Labs LLC | 4 | 9 | 1 | 14 | 2024-2, 2025-1, 2025-2, 2026-1 |
| Tailstorm Health INC | 5 | 6 | 0 | 11 | 2024-2, 2025-1 |
| Apollo Care, LLC | 6 | 2 | 0 | 8 | 2024-2, 2025-2, 2026-1 |
| PQ Pharmacy LLC | 3 | 2 | 2 | 7 | 2024-2, 2025-1, 2025-2 |
| ANNOVEX PHARMA, INC. | 3 | 2 | 0 | 5 | 2025-1 |
| Apothecary Pharma LLC | 0 | 5 | 0 | 5 | 2026-1 |
| Empower Pharma | 2 | 2 | 0 | 4 | 2025-1 |
| Hybrid Pharma | 2 | 2 | 0 | 4 | 2024-2, 2025-1, 2025-2, 2026-1 |
| OurPharma LLC | 3 | 0 | 0 | 3 | 2024-2, 2025-1 |
| AnazaoHealth Corporation | 0 | 2 | 0 | 2 | 2025-1 |
| Eagle Pharma Outsourcing, LLC | 2 | 0 | 0 | 2 | 2025-1 |
| Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories | 2 | 0 | 0 | 2 | 2024-2, 2025-1 |
| Turbare Manufacturing | 2 | 0 | 0 | 2 | 2025-1 |
| Delta Pharma INC | 1 | 0 | 0 | 1 | 2025-1 |
| MedisourceRx | 1 | 0 | 0 | 1 | 2024-2, 2025-1 |
| Olympia Pharmacy | 0 | 0 | 1 | 1 | 2026-1 |
| PGRrx LLC | 0 | 1 | 0 | 1 | 2026-1 |
| Signature Rx | 1 | 0 | 0 | 1 | 2025-1 |
| Wells Pharma of Houston | 1 | 0 | 0 | 1 | 2025-1 |
Every compounded GLP-1 listing
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 54288-846 | BPI Labs LLC | Liraglutide Injection, 18 mg/3 mL (6 mg/mL) | Liraglutide Injection, 18 mg/3 mL (6 mg/mL) | INJECTION | SUBCUTANEOUS | 18 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 73198-151 | Olympia Pharmacy | Liraglutide 6 mg/mL | Liraglutide 6mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 81375-606 | PQ Pharmacy LLC | Liraglutide | Liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2 |
| 81375-614 | PQ Pharmacy LLC | Liraglutide | Liraglutide | INJECTION | SUBCUTANEOUS | 15 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2 |
| 82396-300 | ANNOVEX PHARMA, INC. | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-302 | ANNOVEX PHARMA, INC. | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-305 | ANNOVEX PHARMA, INC. | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71170-495 | Apollo Care, LLC | Semaglutide 12.5 mg | Semaglutide 12.5 mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 71170-640 | Apollo Care, LLC | Semaglutide 1mg and Cyanocobalamin 0.5mg | Semaglutide 1mg and Cyanocobalamin 0.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-650 | Apollo Care, LLC | Semaglutide 2.5mg and Cyanocobalamin 0.5mg | Semaglutide 2.5mg and Cyanocobalamin 0.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-690 | Apollo Care, LLC | Semaglutide 12.5mg and Cyanocobalamin 2.5mg | Semaglutide 12.5mg and Cyanocobalamin 2.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-811 | Apollo Care, LLC | Semaglutide 2.25 mg | Semaglutide 2.25 mg | INJECTION, SOLUTION | SUBCUTANEOUS | .9 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 71170-821 | Apollo Care, LLC | Semaglutide 6.75 mg | Semaglutide 6.75 mg | INJECTION, SOLUTION | SUBCUTANEOUS | 4.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-826 | BPI Labs LLC | Semaglutide Injection, 1 mg/mL | Semaglutide Injection, 1 mg/mL | INJECTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-827 | BPI Labs LLC | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL) | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL) | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-831 | BPI Labs LLC | Semaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL) | Semaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL) | INJECTION | SUBCUTANEOUS | 12.5 mg/2.5 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-833 | BPI Labs LLC | Semaglutide Injection, 2.5mg/mL (1mL vial) | Semaglutide Injection, 2.5mg/mL (1mL vial) | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71791-0200 | Delta Pharma INC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 69852-417 | Eagle Pharma Outsourcing, LLC | Semaglutide 1 mg/mL | Semaglutide 1 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mg | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 69852-517 | Eagle Pharma Outsourcing, LLC | Semaglutide 2.4 mg/mL | Semaglutide 2.4 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 2.4 mg/2.4 mg | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72627-2321 | Empower Pharma | Semaglutide/Cyanocobalamin | Semaglutide/Cyanocobalamin | INJECTION | SUBCUTANEOUS | .5 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72627-2322 | Empower Pharma | Semaglutide/Cyanocobalamin | Semaglutide/Cyanocobalamin | INJECTION | SUBCUTANEOUS | 5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71266-6100 | Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 71266-6110 | Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 26436-5608 | Hybrid Pharma | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1, 2026-1 |
| 26436-5635 | Hybrid Pharma | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1, 2026-1 |
| 70657-1027 | MedisourceRx | Semaglutide | Semaglutide | SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 73013-9000 | OurPharma LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 73013-9001 | OurPharma LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 73013-9002 | OurPharma LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 81375-600 | PQ Pharmacy LLC | Semaglutide | Semaglutide 2.5mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81375-601 | PQ Pharmacy LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81375-605 | PQ Pharmacy LLC | Semaglutide | Semaglutide 5mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 84582-4104 | Signature Rx | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 4 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 81483-0045 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .25 mg/.05 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0046 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .5 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0047 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0048 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1.7 mg/.22 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0049 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 2.4 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 83556-0201 | Turbare Manufacturing | Semaglutide 1 mg/mL | Semaglutide 1 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 83556-0205 | Turbare Manufacturing | Semaglutide 5 mg/mL | Semaglutide 5 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 73702-197 | Wells Pharma of Houston | Semaglutide | Semaglutide injection | INJECTION | INTRAMUSCULAR | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72682-1205 | AnazaoHealth Corporation | Tirzepatide 5mg/mL 2mL | Tirzepatide 5mg/mL Injection 2mL | INJECTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72682-1220 | AnazaoHealth Corporation | Tirzepatide 20mg/mL 2mL | Tirzepatide 20mg/mL 2mL | INJECTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-350 | ANNOVEX PHARMA, INC. | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-351 | ANNOVEX PHARMA, INC. | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71170-610 | Apollo Care, LLC | Tirzepatide 20mg and Pyridoxine 8mg | Tirzepatide 20mg and Pyridoxine 8mg | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL; 4 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-630 | Apollo Care, LLC | Tirzepatide 60mg and Pyridoxine 12mg | Tirzepatide 60mg and Pyridoxine 12mg | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL; 4 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 85091-001 | Apothecary Pharma LLC | Tirzepatide | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 18 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-003 | Apothecary Pharma LLC | Tirzepatide | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 9 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-004 | Apothecary Pharma LLC | Tirzepatide and B12 | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 17 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-005 | Apothecary Pharma LLC | Tirzepatide and B12 | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 8.5 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-006 | Apothecary Pharma LLC | Tirzepatide and Glycine | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 17 mg/1 mL; 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 54288-832 | BPI Labs LLC | Tirzepatide Injection, 30 mg/3 mL | Tirzepatide Injection, 30 mg/3 mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-835 | BPI Labs LLC | Tirzepatide Injection, 10 mg/mL | Tirzepatide Injection, 10 mg/mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-836 | BPI Labs LLC | Tirzepatide Injection, 60 mg/3 mL | Tirzepatide Injection, 60 mg/3 mL | INJECTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-840 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 30 mg/3 mL; 30 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-841 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mL | Tirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL; 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-842 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 30 mg/3 mL; 60 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-848 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 40 mg/4 mL; 40 mg/4 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-859 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 20 mg/2 mL; 20 mg/2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 54288-860 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 68 mg/4 mL; 40 mg/4 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 72627-2323 | Empower Pharma | Tirzepatide/Niacinamide | Tirzepatide/Niacinamide | INJECTION | SUBCUTANEOUS | 8 mg/1 mL; 2 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72627-2324 | Empower Pharma | Tirzepatide/Niacinamide | Tirzepatide/Niacinamide | INJECTION | SUBCUTANEOUS | 2 mg/1 mL; 17 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 26436-5622 | Hybrid Pharma | TIRZEPATIDE 10MG/ML | TIRZEPATIDE 10MG/ML | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1, 2025-2, 2026-1 |
| 26436-5636 | Hybrid Pharma | TIRZEPATIDE 20MG/ML | TIRZEPATIDE 20MG/ML | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1, 2025-2, 2026-1 |
| 85049-420 | PGRrx LLC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 17 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 81375-610 | PQ Pharmacy LLC | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81375-620 | PQ Pharmacy LLC | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0050 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 2.4 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0051 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 5 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0052 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 7.5 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0053 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 10 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0054 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 12.5 mg/.25 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0055 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 15 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
What this file does not show
Only outsourcing facilities that elected to assign NDCs report here, so a facility that compounds a GLP-1 drug without reporting an NDC is not in this file. Every row in the file read carries the outsourcing facility category. FDA’s registered 503B list, inspections and letters for each facility are on its page and on the 503B facilities list.
Common questions
Does an NDC listing mean FDA approved a compounded semaglutide product?
No. FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” The category on these listings is “OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)”.
How often do outsourcing facilities report?
FDA says they report “upon initial registration and in June and December each year” and may update at any time.
Where is the full list of GLP-1 NDC listings?
On the NDC listings page of this site, which also covers bulk ingredient and approved-product listings (467 listings read Nov 15, 2026).
Sources
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.